31 maj 2026
35 min
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
Lyssna på fler avsnitt från
BiotechTV - News
Visar 1–10 av 438 avsnitt
27 juli 2026
15 min
27 juli 2026
24 min
27 juli 2026
24 min
27 juli 2026
24 min
23 juli 2026
26 min
23 juli 2026
16 min
23 juli 2026
2 min
23 juli 2026
8 min
22 juli 2026
30 min
22 juli 2026
19 min